Ipsen Biotech Sas Patent-Cliff Exposure & CMS Drug Spending Portfolio

Ipsen Biotech Sas (US): 1 reconciled FDA prescription therapies, $90.9M 2024 CMS Part D & Medicaid spend, and $9,460 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$90.9M
2024 Medicare Part D Spend$57.7M
2024 Medicaid Spend$33.2M
California HCAI SB 17 FilingsSpecialty launch notice ($9,460 intro WAC)